However, the mechanism of action in bladder cancers of IKZF3 and density lipoprotein-binding protein (HDLbp), which has not been reported, may be a new prospective therapeutic target for immunotherapy in bladder patients and is worthy of further exploration. This evidence concerns the gene IKZF3 and urinary bladder cancer.